Concept visual: Wild Bite Club.
A global commercial license is taking computationally designed enzymes into Reb M production, aiming to use more of the stevia leaf while improving taste, waste and cost.
What Is Changing
The most consequential change in stevia may not be another extract or another flavour-masking blend. It is a different way of making the glycoside that many formulators already want. Instead of treating the naturally limited share of Reb M in a leaf extract as a fixed constraint, protein designers can tune enzymes to convert more of that extract into high-purity Reb M. That reframes sugar reduction as a manufacturing problem: design the catalyst, not just the finished sweetener.
This route has moved beyond platform theory. Arzeda developed the ViaLeaf process and entered a commercial partnership with flavour house MANE in March 2026. By July, independent trade reporting said MANE had secured an exclusive global license to produce and commercialise the technology. Production was already operating in the United States, with European capacity available if required. The central commercial question is therefore no longer whether a designed enzyme can work in a controlled experiment. It is whether the resulting ingredient can make better-tasting stevia sweetness economical enough for everyday foods and drinks.
Where It Could Go
If the cost and sensory claims survive customer-scale use, the immediate opportunity is not a new consumer brand. It is a broader formulation toolbox. Reduced-sugar beverages are the obvious first territory because sweetness quality, solubility and aftertaste are exposed in a simple liquid. Dairy drinks, spoonable products, bakery fillings, sauces and confectionery could follow where sugar contributes bulk, texture or flavour balance that a high-intensity sweetener cannot replace alone.
The stronger commercial model may combine Reb M with flavour modulation and application support rather than sell a single ingredient in isolation. MANE has those complementary capabilities and a global customer base. That could let development teams tune sweetness restoration for a specific matrix while the redesigned enzyme works in the background on supply economics. If successful, protein design becomes less of a biotechnology story and more of an ordinary procurement and reformulation lever.
How It Works
The mechanism begins with a less-processed stevia leaf extract containing several rebaudiosides. Computationally designed enzymes catalyse the conversion of more of those available glycosides into high-purity Reb M. They are not themselves the sweetener proposition; they are production tools that change what the raw extract can yield.
Arzeda says its protein-design platform combines physics-based modelling, AI trained on years of proprietary test data and repeated design-build-test-learn cycles. Candidate proteins are tested under conditions relevant to the intended matrix, while expression, stability, yield, bioprocess and formulation requirements enter the design brief before scale-up. That matters because a catalyst that performs in a clean laboratory buffer may fail in a commercial process.
The distinction from other routes is also important. Independent reporting says ViaLeaf uses bioconversion of genuine stevia leaf extract and is not a fermentation-produced Reb M. In practical terms, the designed enzyme improves a conversion step applied to leaf-derived material. Public sources describe less wasted extract and output above 95% Reb M purity, but they do not disclose enzyme sequences, reaction conditions, conversion yields, catalyst recovery, energy demand or full unit economics. The operating principle is specific; the production recipe remains proprietary.
Why It Matters
Reb M is valued because it can deliver a cleaner, more sugar-like profile than stevia grades associated with pronounced bitterness. Its economics have been the harder part. If only a limited fraction of the useful glycosides in a leaf extract becomes the desired output, processors carry the cost of material that never reaches its highest-value form.
For food consultants, the intriguing shift is where value is created. A more efficient catalyst sits upstream from the final recipe, yet it can alter downstream briefs: lower ingredient cost per unit of sweetness, less dependence on masking systems, wider use beyond premium products and better utilisation of agricultural input. That is more transferable than another sweetener claim. It gives beverage, dairy, bakery and confectionery teams a shared question: can a redesigned processing enzyme remove the economic and sensory compromise that has kept a desirable ingredient from becoming routine?
What to Watch
The clearest confirmation will be named customer products using the ingredient at meaningful scale, followed by repeat orders rather than one-off demonstrations. Consultants should look for disclosed production volumes, regional availability and pricing on a sweetness-equivalent basis. A strong case would compare the new route with Reb A, conventional leaf-derived Reb M and fermentation-derived alternatives using the same finished-product brief.
Sensory evidence should extend beyond supplier descriptions: blinded panels in beverages and at least one more difficult matrix, with data on sweetness onset, lingering, bitterness and flavour interaction. Process evidence should quantify conversion efficiency, residual material, energy use and consistency from batch to batch. Market-specific regulatory clearances and labelling treatment also matter, particularly if the ingredient expands into Europe. Finally, watch whether customers can reduce masking flavours or total sweetener dosage without introducing new texture or stability problems. A commercial license establishes a route to market; repeatable formulation results will determine whether the route changes category economics.
The WBC Read
The signal is persuasive because the mechanism, manufacturing logic and route to commercial scale align. Designed enzymes address a real stevia bottleneck, and the involvement of an established flavour and ingredient company makes customer testing and distribution plausible. The concept is also useful beyond one sweetener: it shows how protein design can improve the conversion economics of a familiar agricultural feedstock rather than invent an entirely new food.
The uncertainty is concentrated in the undisclosed numbers. Claims about lower waste, better taste and affordability need comparable yield, cost, sensory and customer data. Until those appear, this is best treated as a credible ingredient-platform transition with operating momentum, not proof that Reb M has solved every reformulation compromise. The next meaningful evidence will come from factories, formulation benches and repeat purchasing.